Postdischarge major bleeding, myocardial infarction, and mortality risk after coronary artery bypass grafting.

Coronary Artery Bypass Myocardial Infarction

Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
26 Dec 2023
Historique:
received: 28 08 2023
accepted: 22 11 2023
medline: 27 12 2023
pubmed: 27 12 2023
entrez: 26 12 2023
Statut: aheadofprint

Résumé

To investigate the incidence and mortality risk associated with postdischarge major bleeding after coronary artery bypass grafting (CABG), and relate this to the incidence of, and mortality risk from, postdischarge myocardial infarction. All patients undergoing first-time isolated CABG in Sweden in 2006-2017 and surviving 14 days after hospital discharge were included in a cohort study. Individual patient data from the SWEDEHEART Registry and five other mandatory nationwide registries were merged. Piecewise Cox proportional hazards models were used to investigate associations between major bleeding, defined as hospitalisation for bleeding, with subsequent mortality risk. Similar Cox proportional hazards models were used to investigate the association between postdischarge myocardial infarction and mortality risk. Among 36 633 patients, 2429 (6.6%) had a major bleeding event and 2231 (6.1%) had a myocardial infarction. Median follow-up was 6.0 (range 0-11) years. Major bleeding was associated with higher mortality risk <30 days (adjusted HR (aHR)=20.2 (95% CI 17.3 to 23.5)), 30-365 days (aHR=3.8 (95% CI 3.4 to 4.3)) and >365 days (aHR=1.8 (95% CI 1.7 to 2.0)) after the event. Myocardial infarction was associated with higher mortality risk <30 days (aHR=20.0 (95% CI 16.7 to 23.8)), 30-365 days (aHR=4.1 (95% CI 3.6 to 4.8)) and >365 days (aHR=1.8 (95% CI 1.7 to 2.0)) after the event. The increase in mortality risk associated with a postdischarge major bleeding after CABG is substantial and is similar to the mortality risk associated with a postdischarge myocardial infarction.

Identifiants

pubmed: 38148160
pii: heartjnl-2023-323394
doi: 10.1136/heartjnl-2023-323394
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: AJ has received fees for consultancy from AstraZeneca, Werfen and LFB Biotechnologies, all unrelated to the present work.

Auteurs

Erik Björklund (E)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden erik.bjorklund@gu.se.
Department of Medicine, Southern Älvsborg Hospital, Borås, Sweden.

Philip Enström (P)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Susanne J Nielsen (SJ)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Hans Tygesen (H)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, Southern Älvsborg Hospital, Borås, Sweden.

Andreas Martinsson (A)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Emma C Hansson (EC)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Martin Lindgren (M)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Carl-Johan Malm (CJ)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Aldina Pivodic (A)

Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden.
APNC Sweden, Gothenburg, Sweden.

Anders Jeppsson (A)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Classifications MeSH